Ignite Creation Date:
2024-05-06 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 2:20 PM
Study NCT ID:
NCT05159193
Status:
RECRUITING
Last Update Posted:
2024-02-02
First Post:
2021-11-25
Brief Title:
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Organization:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study Overview
Official Title:
A Multicentre Open-label Randomised Trial of Neoadjuvant Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter open label non-inferiority randomized controlled clinical study
The aim of this study is to evaluate the efficacy and safety of a pegylated liposomal doxorubicin cyclophosphamide followed by docetaxel plus trastuzumab and pertuzumab PLD C HP followed by THP regimen compared with a docetaxel carboplatin plus trastuzumab and pertuzumab TCbHP regimen in the neoadjuvant treatment of HER-2-positive breast cancer
The aim of this study is to evaluate the efficacy and safety of a pegylated liposomal doxorubicin cyclophosphamide followed by docetaxel plus trastuzumab and pertuzumab PLD C HP followed by THP regimen compared with a docetaxel carboplatin plus trastuzumab and pertuzumab TCbHP regimen in the neoadjuvant treatment of HER-2-positive breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None